German fragrance and flavours house Symrise has just last night inked a deal with Swedish probiotics firm Probi to develop a stand-alone R&D project with oral probiotic supplements the most likely product out of the pipeline in 2014-2015.
BASF on Friday invited the Scottish First Minister, Alex Salmond, to officially open its newly acquired and now expanded high concentration omega-3 facility on the Isle of Lewis in the Hebrides, west Scotland.
BASF’s ever-expanding nutrition unit says its €644m bid last week bid for Norwegian omega-3 firm, Pronova Biopharma, is as important for its food supplements business as its pharmaceutical operations.
PPMA is fearful that the Government of Pakistan’s recent call for more foreign investment in the local pharma sector will go unheard because the industry is already overcrowded.
in-PharmaTechnologist brings you a round-up of the latest new facilities and expansions for drugsmakers, including added cytotoxic capabilities for BTL, Jubilant’s launch of a special economic zone in India and plans for a $20m API plant for Omkar.
Danone and Mead Johnson may make a joint bid for the €8bn infant nutrition-dominated Pfizer nutrition business that is up for sale, according to press reports.
Rousselot says its acquisition of Eastman Kodak’s Gel Corporation will boost its gelatine production capacity and help it meet soaring drug industry demand.
R&D software firm Accelrys says it will speed up the pharma QA/QC process and reduce the compliance risk ten-fold through its $35m takeover of VelQuest.
AmerisourceBergen has bought informatics firm IntrinsiQ for $35m (€25m) continuing the spending spree it began earlier this week with the acquisition of market access consultancy Premier Source.
DMV-Fonterra excipients (DFE) will buy Indian manufacturer Brahmar Cellulose Private Limited (BCPL) to strengthen its position in the pharmaceutical excipient market and reduce costs.
International Chemical Investors Group (ICIG) will take over Roche’s Colorado API plant in a bid to gain footing in the peptide manufacturing industry.
BioMarin will buy Pfizer’s biologics manufacturing plant in Shanbally, Cork, Ireland to add production capacity for its candidate mucopolysaccharidosis treatment.
GlaxoSmithKline (GSK) has announced plans to buy its joint venture Shenzhen GSK Neptunus Biologicals (GSKNB) to expand influenza vaccine production capacity in China.
Ashland will buy International Specialty Products (ISP) in a deal designed to expand it's business in less cyclical, high-growth markets such as pharmaceuticals and personal care.
Watson Pharmaceuticals has bought Greek generics firm Specifar Pharmaceuticals, bringing to an end a busy month of deal making in the non-branded drug sector.
UK-based drugmaker Shire has unveiled plans to buy Advanced BioHealing (ABH) citing the lack of generic competition in the regenerative medicines sector as a factor.
Oystar has sold its processing tech units, Huttlin and Manesty, to Bosch in a deal that continues its effort to refocus on primary and secondary packaging.
Nano Terra, a surface engineering and nanotechnology company based in Brighton Massachusetts, US, has struck a deal to acquire neighbouring drug developer, Surface Logix.
Pharmaceutical giant Pfizer has agreed to sell Capsugel, its drug delivery technology unit, to US investment group Kohlberg Kravis Roberts & Co (KKR) for $2.4bn (€1.7bn).
Gerresheimer has bought Brazilian pharmaceutical plastic packaging maker Vedat, citing rapid growth of the country’s drug market, particularly the generics segment, as the main driver for the acquisition.
